Collaborating with a Clinician Case Study: Taking an oesophageal cancer therapeutic to clinical trial

A Research Translation Committee Seminar

UQDI’s TRI-based Professor Ian Frazer, and his clinical collaborator, PA Hospital’s Professor Sandro Porceddu, are leading the pioneering Durvax Trial for head and neck cancer associated with Human Papillomavirus (HPV). This Phase I clinical trial is using a HPV vaccine combined with an immunotherapy drug to treat patients. It follows the initial success of first-in-human trials proving the safety of the new HPV vaccine developed by Professor Frazer, and developed by Brisbane-based Jingang Medicine (Australia) Pty Ltd.

At this seminar you’ll hear from Professors Fazer and Porceddu about their unique clinical trial, which involves a completely new approach to treating cancer, as well as their collaboration and how it was vital to progressing this clinical trial.